Advanced imaging technology applications in cytology

Pantanowitz, Liron; Preffer, Frederic I.; Wilbur, David C.

doi:10.1002/dc.23898

Cited by 9 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytology is an established technology for the detection of cancers and their precursors, for example of the bladder 31 , lung 32 and cervix 33 . Recent years have witnessed innovative solutions to the detection of Barrett's oesophagus 34 and oral cancer 35 using cytology, offering hope for early detection strategies 36 . Here we hijack the natural shed of endometrial tumours via PMB to similarly develop a novel approach to endometrial cancer detection.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of cytology for the detection of endometrial cancer in urine and vaginal samples

et al. 2021

View full text Add to dashboard Cite

Postmenopausal bleeding triggers urgent investigation by sequential invasive tests that are avoidable for the 90–95% of women who do not have endometrial cancer. A simple, non-invasive tool that accurately identifies cancer and safely reassures healthy women could transform patient care. Here we report, in a cross-sectional diagnostic accuracy study of 103 women with known cancer and 113 with unexplained postmenopausal bleeding, that urine and vaginal cytology has a combined sensitivity of 91.7% (95% CI 85.0%, 96.1%) and specificity of 88.8% (81.2%, 94.1%) for gynecological cancer detection. Cytology identifies 91 endometrial, two fallopian tube and one cervical cancer from 103 known cancer cases. In women with unexplained postmenopausal bleeding, cytology identifies all four endometrial cancers and three others (cervical, ovarian and bladder), for a 12/107 (11.2%) false positive rate. We show proof-of-principle that endometrial cancer can be detected in urine and vaginal fluid. Prospective validation of these findings will support incorporation of this non-invasive test into clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of cytology for the detection of endometrial cancer in urine and vaginal samples

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cellular imaging and analysis platforms, such as CellCT (VisionGate) and Totalys (Becton Dickinson), permit capturing hundreds of morphological measurements in individual cells of clinical samples, resulting in the generation of 3‐dimensional images. The ability to create high‐resolution biosignatures from intact cells in sputum samples and liquid‐based preparations provides complementary imaging approaches to improve upon the efficiency of lung cancer screening with low‐dose CT 27 and a Papanicolaou (Pap) test or human papillomavirus (HPV) genotyping for cervical cancer screening 28 …”

Section: Cancer Screening and Early Detectionmentioning

confidence: 99%

“…The ability to create high-resolution biosignatures from intact cells in sputum samples and liquid-based preparations provides complementary imaging approaches to improve upon the efficiency of lung cancer screening with low-dose CT 27 and a Papanicolaou (Pap) test or human papillomavirus (HPV ) genotyping for cervical cancer screening. 28…”

Section: Imaging Biomarkersmentioning

confidence: 99%

Blueprint for cancer research: Critical gaps and opportunities

Elmore

Greer

Daniels

et al. 2020

CA A Cancer J Clinicians

View full text Add to dashboard Cite

We are experiencing a revolution in cancer. Advances in screening, targeted and immune therapies, big data, computational methodologies, and significant new knowledge of cancer biology are transforming the ways in which we prevent, detect, diagnose, treat, and survive cancer. These advances are enabling durable progress in the goal to achieve personalized cancer care. Despite these gains, more work is needed to develop better tools and strategies to limit cancer as a major health concern. One persistent gap is the inconsistent coordination among researchers and caregivers to implement evidence‐based programs that rely on a fuller understanding of the molecular, cellular, and systems biology mechanisms underpinning different types of cancer. Here, the authors integrate conversations with over 90 leading cancer experts to highlight current challenges, encourage a robust and diverse national research portfolio, and capture timely opportunities to advance evidence‐based approaches for all patients with cancer and for all communities.

show abstract

“…Future developments, including single cell technology, digital pathology platforms and machine learning algorithms are on the horizon. These digital solutions may be trained to recognise malignant cells by morphology, and when combined with adjunctive immunocytochemistry, may pinpoint site(s) of origin 16 . The utility of urogenital cytology as a screening tool for asymptomatic patients is untested but could provide the opportunity for home‐based self‐sampling for high risk patients, for example in Lynch syndrome, who may be at increased risk of both endometrial and urothelial tumours, and further research is needed.…”

Section: Discussion/conclusionmentioning

confidence: 99%

Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology

Narine

Rana

Shelton

et al. 2021

Diagnostic Cytopathology

View full text Add to dashboard Cite

Novel diagnostics for uterine cancer are urgently needed to reduce the burden of invasive testing for the majority of healthy women with postmenopausal bleeding. We have previously shown that uterine cancer cells can be detected by cytology in urine and vaginal samples with high diagnostic accuracy. Here, we demonstrate its potential to distinguish malignant cells of different aetiologies in the same urogenital biofluid sample according to their distinctive morphology and immunoprofiles. Synchronous tumours of the urogenital tract are uncommon but can cause diagnostic confusion, delays and poor outcomes. A 79‐year‐old woman presented to accident and emergency with postmenopausal bleeding. Voided urine and Delphi screener‐collected vaginal samples were assessed by cytology and immunocytochemistry. Two malignant cell populations with distinct morphology and immunophenotypes consistent with synchronous uterine and urothelial tumours were identified. Subsequent routine diagnostics confirmed concurrent uterine carcinosarcoma and high‐grade urothelial carcinoma of the bladder. This case demonstrates that cytology and adjunctive immunocytochemistry can simultaneously identify and phenotype cancers of different aetiologies from a single urogenital biofluid sample. This can help rationalise diagnostic pathways in complex, unusual cases of dual urogenital primaries.

show abstract

Advanced imaging technology applications in cytology

Cited by 9 publications

References 43 publications

Diagnostic accuracy of cytology for the detection of endometrial cancer in urine and vaginal samples

Diagnostic accuracy of cytology for the detection of endometrial cancer in urine and vaginal samples

Blueprint for cancer research: Critical gaps and opportunities

Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology

Contact Info

Product

Resources

About